+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bone Marrow Transplant - Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5141034
The global market for Bone Marrow Transplant was estimated at US$11.1 Billion in 2023 and is projected to reach US$14.7 Billion by 2030, growing at a CAGR of 4.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Bone Marrow Transplant Market - Key Trends and Drivers Summarized

How Does Bone Marrow Transplant Save Lives and Why Is It Crucial?

Bone marrow transplant (BMT) is a life-saving medical procedure that plays a pivotal role in the treatment of various life-threatening diseases, particularly blood cancers such as leukemia, lymphoma, and multiple myeloma. The procedure involves replacing damaged or diseased bone marrow with healthy stem cells, which can regenerate the blood and immune system, offering patients a second chance at life. There are two main types of bone marrow transplants: autologous, where the patient's own stem cells are harvested, treated, and then returned to their body, and allogeneic, where the stem cells are donated by another person, often a relative or a matched unrelated donor. The choice between these methods depends on the patient's condition, the availability of a suitable donor, and the specific disease being treated. BMT is not only essential for treating cancer but is also used to manage severe blood disorders such as aplastic anemia and genetic conditions like sickle cell disease and thalassemia. This procedure has been transformative in the field of hematology, offering hope to patients who once had limited treatment options.

What Are the Advancements and Techniques in Bone Marrow Transplantation?

Over the years, advancements in bone marrow transplantation techniques have significantly improved patient outcomes and expanded the range of treatable conditions. One of the major innovations is the development of reduced-intensity conditioning (RIC) transplants, which allow older patients or those with other health issues to undergo the procedure with lower doses of chemotherapy and radiation. This approach has made BMT accessible to a broader patient population, reducing the risks associated with traditional high-dose conditioning regimens. Another significant advancement is the use of haploidentical transplants, where a donor is only a half-match to the recipient. This technique has greatly increased the pool of potential donors, making it easier for patients to find a match, particularly in ethnically diverse populations where full matches may be rare. Additionally, improvements in stem cell harvesting, including the use of peripheral blood stem cells and cord blood, have provided more options for stem cell sources, each with its own set of benefits in terms of engraftment speed and immune recovery. These technological advancements have collectively enhanced the effectiveness, safety, and accessibility of bone marrow transplants.

What Challenges and Complications Are Associated with Bone Marrow Transplants?

Despite the life-saving potential of bone marrow transplants, the procedure is not without significant challenges and risks. One of the most serious complications is graft-versus-host disease (GVHD), which occurs when the donated stem cells attack the recipient's body, leading to potentially life-threatening conditions affecting the skin, liver, and gastrointestinal tract. Advances in immunosuppressive therapies and post-transplant care have helped to manage and mitigate the severity of GVHD, but it remains a major concern, particularly in allogeneic transplants. Another challenge is the high risk of infection during the period of immune recovery post-transplant, as patients are extremely vulnerable due to the suppression of their immune systems. The development of prophylactic antibiotics and antiviral drugs has improved infection control, but it requires meticulous care and monitoring. Additionally, the success of a bone marrow transplant heavily depends on the compatibility between donor and recipient, and finding a suitable match can be difficult, especially for patients from minority ethnic backgrounds. Lastly, the procedure is expensive and resource-intensive, limiting access for many patients globally, especially in low-resource settings. Addressing these challenges is critical to improving the overall success rates and accessibility of bone marrow transplants.

What's Fueling the Expansion of the Bone Marrow Transplant Market?

The growth in the bone marrow transplant market is driven by several factors that reflect advancements in medical technology and changing healthcare demands. The increasing prevalence of blood cancers and other hematological disorders has led to a higher demand for bone marrow transplants as a treatment option. Technological advancements, such as the development of improved matching techniques and the expansion of donor registries, have made it easier to find compatible donors, increasing the availability and success rates of transplants. The rise of personalized medicine, which tailors treatments to the genetic profile of individual patients, is also driving growth in this market, as it enables more precise matching and better outcomes. Moreover, the aging population is contributing to the market expansion, as older adults with conditions like myelodysplastic syndromes are increasingly undergoing transplants thanks to advancements like reduced-intensity conditioning. Additionally, growing awareness of the importance of donor registration and the expansion of public and private cord blood banks are increasing the availability of stem cells, making transplants more accessible to a wider patient population. Finally, increased healthcare spending and investment in research and development are fueling innovation in this field, further propelling market growth and improving patient outcomes.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Myeloma Indication segment, which is expected to reach US$4.8 Billion by 2030 with a CAGR of a 4.1%. The Leukemia Indication segment is also set to grow at 4.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $2.9 Billion in 2023, and China, forecasted to grow at an impressive 6.3% CAGR to reach $3.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Bone Marrow Transplant Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Bone Marrow Transplant Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Bone Marrow Transplant Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Allcells LLC, American Type Culture Collection (ATCC), Beike Biotechnology Co., Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 38 Featured):

  • Allcells LLC
  • American Type Culture Collection (ATCC)
  • Beike Biotechnology Co., Ltd.
  • BioTime, Inc.
  • Cellular Dynamics International
  • Corestem, Inc.
  • Gamida Cell Ltd.
  • HemaCare Corporation
  • Lifeline Cell Technology
  • Lonza Group Ltd.
  • Mesoblast Ltd.
  • Promocell GmbH
  • ReachBio LLC
  • Sanofi-aventis U.S. LLC

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Bone Marrow Transplant - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Blood Cancers Drives Demand for Bone Marrow Transplants
  • Advancements in Stem Cell Harvesting Techniques Propel Growth in Bone Marrow Transplant Procedures
  • Rising Success Rates and Improved Outcomes Strengthen Business Case for Bone Marrow Transplants
  • Expansion of Donor Registries and Matching Technologies Expands Addressable Market Opportunity
  • Growing Use of Cord Blood as a Stem Cell Source Drives Adoption of Bone Marrow Transplant Procedures
  • Technological Innovations in Immunosuppressive Treatments Propel Growth in Allogeneic Transplants
  • Rising Awareness and Education About Bone Marrow Donation Generate Increased Donor Participation
  • Challenges in Managing Graft-Versus-Host Disease (GVHD) Create Opportunities for Innovation in Post-Transplant Care
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Bone Marrow Transplant Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Bone Marrow Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: USA Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: USA 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 29: USA Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: USA Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: USA 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
CANADA
  • Table 32: Canada Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Canada 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 35: Canada Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Canada 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
JAPAN
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 38: Japan Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Japan 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 41: Japan Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Japan Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Japan 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
CHINA
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 44: China Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: China Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: China 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 47: China Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: China Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: China 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
EUROPE
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 50: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Bone Marrow Transplant by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Europe 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
FRANCE
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 59: France Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: France Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: France 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 62: France Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: France Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: France 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
GERMANY
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 65: Germany Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: Germany 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 68: Germany Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: Germany Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: Germany 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
ITALY
  • Table 71: Italy Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Italy 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 74: Italy Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Italy Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Italy 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 77: UK Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: UK Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: UK 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 80: UK Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: UK Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: UK 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
SPAIN
  • Table 83: Spain Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: Spain Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: Spain 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 86: Spain Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Spain Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: Spain 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
RUSSIA
  • Table 89: Russia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Russia Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Russia 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 92: Russia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Russia Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Russia 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Rest of Europe Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Rest of Europe 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Rest of Europe Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Rest of Europe 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Bone Marrow Transplant by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 103: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 106: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 109: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
AUSTRALIA
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • Allcells LLC
  • American Type Culture Collection (ATCC)
  • Beike Biotechnology Co., Ltd.
  • BioTime, Inc.
  • Cellular Dynamics International
  • Corestem, Inc.
  • Gamida Cell Ltd.
  • HemaCare Corporation
  • Lifeline Cell Technology
  • Lonza Group Ltd.
  • Mesoblast Ltd.
  • Promocell GmbH
  • ReachBio LLC
  • Sanofi-aventis U.S. LLC

Table Information